CALCIJEX (calcitriol) by AbbVie is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). First approved in 1986.
Drug data last refreshed 13h ago · AI intelligence enriched Yesterday
CALCIJEX (calcitriol) is the active hormonal form of vitamin D3, administered by injection to regulate calcium and phosphorus metabolism. It is indicated for patients with chronic kidney disease who cannot adequately synthesize calcitriol endogenously, treating hypocalcemia and secondary hyperparathyroidism. The drug works by binding to calcitriol receptors in the intestine and bone to stimulate calcium absorption and correct metabolic bone disease of renal failure.
Product approaching loss of exclusivity with limited Part D market data; brand team likely focused on lifecycle extension and managed care retention.
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on CALCIJEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
Oral Calcitriol With Ketoconazole in CRPC
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
CALCIJEX offers limited career growth given its LOE-approaching status and zero linked job openings. Roles on this product are primarily defensive, focused on maintaining market share, optimizing contracting, and managing the transition to generic competition rather than driving innovation or expansion.